Efficacy News and Research

RSS

Rib-X Pharmaceuticals to demonstrate three presentations at Antibacterial Drug Development Conference

Rib-X Pharmaceuticals, Inc., a development-stage antibiotics company with a broad product pipeline based on its innovative discovery platform, today announced that it will be presenting three separate presentations at the Cambridge Healthtech Institute's 4th Annual Antibacterial Drug Development Conference, Resistance is Futile: The Challenge of Antibacterial Drug Development, April 27 - 28, in San Diego, CA.

27 Apr 2010

People infected with gastrointestinal worms respond better to injected vaccines

According to the World Health Organization, two billion people around the globe suffer from chronic parasitic worm infections, which, in addition to causing illness and developmental delay, are also suspected to interfere with the effectiveness of ordinary vaccines, making their victims more vulnerable to life-threatening diseases. A recent discovery by researchers at the Trudeau Institute promises to bypass these obstacles and help deliver more effective vaccines to these people, boosting their protection against common childhood diseases.

27 Apr 2010

Avivia Health announces new portal with digital health coaching and interactive tools for employee members

To help employee members take a more proactive role in managing their own health programs, Avivia Health From Kaiser Permanente today announced the introduction of Your Health Center, a new portal based on Web 2.0 technology that provides user members with powerful digital health coaching and interactive tools. Avivia Health is the only national provider of Wellness and Condition Management Solutions based on 60 years of evidence-based practices by its parent organization, Kaiser Permanente.

27 Apr 2010

LCT receives grant of $500,000 for Phase II clinical trial of DIABECELL in New Zealand

Living Cell Technologies Limited, a global company pioneering the development of a cell implant to treat diabetes, has received a grant of US$500,000 for its on-going Phase II clinical trial of DIABECELL in New Zealand from the Juvenile Diabetes Research Foundation International, a world leader in setting the agenda for diabetes research and the largest charitable funder and advocate for research in type 1 diabetes.

27 Apr 2010

VertiFlex enrolls 100 patients in Superion Interspinous Spacer IDE clinical trial

VertiFlex, Inc., a leading innovator of minimally invasive and motion preserving spinal surgery technologies, today announced that 100 patients have been enrolled in its pivotal IDE clinical trial of the Superion Interspinous Spacer (ISS).

27 Apr 2010

New syndicated report covers the use of DMAs for treatment of MS published

BioTrends is pleased to announce the publication of a new syndicated report, TreatmentTrends: Multiple Sclerosis. This report covers the use of disease-modifying agents for the treatment of multiple sclerosis, as well as attitudes and perceptions toward these products, advantages and disadvantages, ideal patient types, barriers to growth and expected future use.

26 Apr 2010

First patient enrolled in Phase II clinical trial of E10030 for treatment of wet age-related AMD

Ophthotech Corp., a privately held biopharmaceutical company focused on developing ophthalmic therapies for back-of-the-eye diseases, today announced that the first patient has been enrolled in its Phase II randomized, controlled clinical trial of E10030, an anti-PDGF aptamer, in combination with Lucentis® for the treatment of wet age-related macular degeneration (AMD).

26 Apr 2010

Covidien introduces PENNSAID to the U.S. market

Covidien, a leading global provider of healthcare products, has introduced PENNSAID (diclofenac sodium topical solution) 1.5% w/w to the U.S. market. PENNSAID is the only FDA-approved topical non-steroidal anti-inflammatory drug in a vehicle solution containing dimethyl sulfoxide, a known penetrating agent. It is indicated for treatment of the signs and symptoms of osteoarthritis of the knee(s).

26 Apr 2010

Kinetic Concepts introduces V.A.C.Via Therapy System

Kinetic Concepts, Inc. today introduced V.A.C.Via Therapy System, a next-generation negative pressure wound therapy solution that offers clinicians and patients a mobile healing technology with the proven benefits and outcomes of V.A.C. Therapy.

26 Apr 2010

Pevion Biotech to present positive results of PEV4 RSV vaccine candidate at Vaccine Innovation Meeting

Pevion Biotech, the Swiss vaccine company, today announced that it has successfully completed the preclinical safety and efficacy studies of its RSV vaccine candidate PEV4. The vaccine candidate is a modern subunit vaccine candidate against respiratory syncytial virus (RSV), which is based on a recombinant RSV-F protein formulated with Pevion Biotech's proprietary and market-validated virosome technology platform.

26 Apr 2010

JHUSON introduces Text4Baby program to provide parenting tips to new parents

Having a baby is a very exciting time for new parents, with all the preparation and anticipation that comes with it. But how do parents find help and assistance—from prenatal care to parenting tips? Researchers at the Johns Hopkins University School of Nursing have come up with innovative ways to provide parenting tips to new parents of all demographics.

24 Apr 2010

ACP to provide physicians, patients with evidence-based recommendations for clinical problems

Building on its existing foundation of clinical and public policies, the American College of Physicians announced plans to provide physicians and patients with evidence-based recommendations for specific interventions for a variety of clinical problems.

24 Apr 2010

AFFiRiS' AD02 Alzheimer's vaccine candidate in phase II clinical testing

AFFiRiS AG's clinical Alzheimer's vaccine candidate AD02 has already progressed to phase II clinical testing. It may therefore be possible to confirm the efficacy of the vaccine as early as during 2012. Indeed the start of this efficacy study comes only five months after the completion of the corresponding phase I study. The company is active in several disease areas and is currently developing a total of twelve prospective products in all stages of the development pipeline up to clinical phase II.

24 Apr 2010

NDSsi's ZeroWire Duo wireless Full HD video solution receives FDA clearance

NDS Surgical Imaging today announced it has received U.S. Food and Drug Administration 510(k) clearance for ZeroWire Duo, a Class II medical-grade wireless Full HD video solution for minimally-invasive surgery, GI and interventional suites.

24 Apr 2010

NREF announces fellowship funding for 2010-2011

The Neurosurgery Research and Education Foundation (NREF), which reached an agreement with Codman & Shurtleff, Inc. (Codman) in December 2009 to provide funding to the NREF in support of the Foundation's new post-residency, clinical fellowship grant program, is pleased to announce that the following programs have been awarded fellowship funding for 2010-2011: Baylor College of Medicine (pediatric neurosurgery), Brigham & Women's Hospital (general neurosurgery),

23 Apr 2010

GenVec's 2009 revenues down 8%: MicroStockProfit.com

MicroStockProfit.com announces an investment report featuring GenVec Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

23 Apr 2010

Geron scientists highlight importance of telomerase inhibitor, GRN163L at AACR 2010

Geron Corporation today announced five presentations by Geron scientists and collaborators on the company's telomerase inhibitor, imetelstat sodium, including the drug's activity against cancer stem cells, at the 101st American Association for Cancer Research annual meeting held in Washington D.C.

23 Apr 2010

Celator Pharmaceuticals presents data on CPX-351 Liposome Injection and HDPN formulation

Celator Pharmaceuticals today announced data from animal studies demonstrating the superior bone marrow uptake of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection, its lead clinical-stage program, as well as the enhanced circulation kinetics and efficacy of its preclinical hydrophobic docetaxel prodrug nanoparticle (HDPN) formulation were presented at the 101st Annual Meeting of the American Association for Cancer Research in Washington, DC (Abstracts 3698 and 5534).

23 Apr 2010

Pfizer announces discontinuation of SUN 1170 Phase 3 study of Sutent in HCC

Pfizer Inc. announced today the discontinuation of the SUN 1170 Phase 3 open-label study of Sutent(r) (sunitinib malate) in advanced hepatocellular carcinoma, or liver cancer. Following a review by the independent Data Monitoring Committee, the study was discontinued based on a higher incidence of serious adverse events in the sunitinib arm compared to the sorafenib arm and the fact that sunitinib did not meet the criteria to demonstrate that it was either superior or non-inferior to sorafenib in the survival of patients with advanced hepatocellular cancer.

23 Apr 2010

Molecular mechanisms of hypertension, its diagnosis and treatment to be focused at ASBMB's symposium

About 1 billion people around the world suffer from hypertension. The molecular mechanisms of this disease, its diagnosis and treatment will be the focus of a lecture series at the American Society for Biochemistry and Molecular Biology's annual meeting in Anaheim, Calif. The talks will take place from Monday, May 26 through Wednesday, April 28 in room 304C of the Anaheim Convention Center.

23 Apr 2010

Efficacy News and Research

Rib-X Pharmaceuticals to demonstrate three presentations at Antibacterial Drug Development Conference

People infected with gastrointestinal worms respond better to injected vaccines

Avivia Health announces new portal with digital health coaching and interactive tools for employee members

LCT receives grant of $500,000 for Phase II clinical trial of DIABECELL in New Zealand

VertiFlex enrolls 100 patients in Superion Interspinous Spacer IDE clinical trial

New syndicated report covers the use of DMAs for treatment of MS published

First patient enrolled in Phase II clinical trial of E10030 for treatment of wet age-related AMD

Covidien introduces PENNSAID to the U.S. market

Kinetic Concepts introduces V.A.C.Via Therapy System

Pevion Biotech to present positive results of PEV4 RSV vaccine candidate at Vaccine Innovation Meeting

JHUSON introduces Text4Baby program to provide parenting tips to new parents

ACP to provide physicians, patients with evidence-based recommendations for clinical problems

AFFiRiS' AD02 Alzheimer's vaccine candidate in phase II clinical testing

NDSsi's ZeroWire Duo wireless Full HD video solution receives FDA clearance

NREF announces fellowship funding for 2010-2011

GenVec's 2009 revenues down 8%: MicroStockProfit.com

Geron scientists highlight importance of telomerase inhibitor, GRN163L at AACR 2010

Celator Pharmaceuticals presents data on CPX-351 Liposome Injection and HDPN formulation

Pfizer announces discontinuation of SUN 1170 Phase 3 study of Sutent in HCC

Molecular mechanisms of hypertension, its diagnosis and treatment to be focused at ASBMB's symposium

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News